CPhI Worldwide publishes its forecasts for the pharmaceutical market at the beginning of 2022, based on a survey of more than 350 pharmaceutical executives and the expert opinions of 10 CPhI employees.
The results indicate that more than 30 FDA approvals for new drugs are possible in 2022. This leads to a Production pressure on CDMOs and higher margins and profits for suppliers.
"In view of the In the race to develop and manufacture vaccines worth billions, the pandemic has put immense pressure on global production capacity and further expanded capacities for equipment and consumables, with vials and disposable components, filters and bags being particularly affected."
Dan Stanton, editor at BioProcess Insider
In the first half of 2022 in particular, the Prices for raw materials continue to risepredicts Stephan Schmidinger, Partner at Kemiex. Restricted availability could further delay deliveries and thus jeopardise the dynamic problems in the supply chain that prevailed in 2021 will continue.
However, the report also positive developments such as the global increase in sustainable procurement. 2022 could bring an acceleration of corporate transparency and sustainability strategies.
"The CPhI Pharma Trends 2022 Report is not only concerned with some of the largest Tensions and obstaclesthe industry will be confronted with in 2022, but also with the innovative solutions it is developing to overcome them."
Tara Dougal, Head of Content and Insights, Pharma, Informa Markets
Source: CPhI Worldwide
